ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "PDL BioPharma, Inc." (PDLI) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"PDL BioPharma, Inc." (PDLI)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: ENTA, AGIO, MACK, MDXG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up downgrade
service keys

"PDL BioPharma, Inc."© quotemedia

Company Profile

PDL BioPharma, Inc. engages in intellectual property asset management and royalty bearing assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Recent News: "PDL BioPharma, Inc."